About MannKind

MannKind Corporation (Nasdaq and TASE: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh), approved in 2014 by the U.S. Food and Drug Administration, is a rapid-acting inhaled insulin therapy indicated to improve glycemic control in adults with diabetes. Taken at the start of a meal using a specially designed inhaler, Afrezza dissolves rapidly upon inhalation to the deep lung and delivers insulin quickly to the bloodstream. Peak insulin levels are achieved within 12 to 15 minutes of use and help to control post-meal blood sugar spikes that affect HbA1C levels.  More >

 

                    follow me on twitter       find us on facebook

 
For more information about AFREZZA, please visit www.Afrezza.com.

Update on Medicare/Medicaid Coverage

 

We recently learned that there was a lapse in Medicare and Medicaid coverage for Afrezza as a result of the transition to MannKind’s NDC codes. This issue impacted prescriptions last week and is anticipated to affect reported prescription counts only for the month of August. If you are on Medicare or Medicaid and having trouble filling your prescription for Afrezza, please contact MannKind Cares at 844-323-7399 (1-844-3Afrezza) for an interim solution. We expect that patients will not have any problem filling or refilling their Medicare or Medicaid prescription for Afrezza starting September 1, 2016. We apologize for this inconvenience.

 

News & Events

   
Aug 25, 2016 Securities Class Action Against MannKind Dismissed More >
Aug 08, 2016 MannKind Corporation Reports 2016 Second Quarter Financial Results More >
Aug 01, 2016 Mannkind Assumes Responsibility for Distribution of Afrezza® and Launches Patient... More >